Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Sold by T. Rowe Price Investment Management Inc.

T. Rowe Price Investment Management Inc. lowered its position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) by 2.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,466,721 shares of the company's stock after selling 267,668 shares during the period. T. Rowe Price Investment Management Inc. owned about 18.50% of Black Diamond Therapeutics worth $22,399,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in Black Diamond Therapeutics by 429.6% in the 4th quarter. JPMorgan Chase & Co. now owns 18,929 shares of the company's stock valued at $41,000 after acquiring an additional 15,355 shares during the last quarter. Intech Investment Management LLC raised its holdings in Black Diamond Therapeutics by 49.1% in the 4th quarter. Intech Investment Management LLC now owns 19,247 shares of the company's stock valued at $41,000 after acquiring an additional 6,340 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Black Diamond Therapeutics in the 4th quarter valued at about $42,000. Wells Fargo & Company MN raised its holdings in Black Diamond Therapeutics by 41.8% in the 4th quarter. Wells Fargo & Company MN now owns 20,119 shares of the company's stock valued at $43,000 after acquiring an additional 5,932 shares during the last quarter. Finally, Sei Investments Co. acquired a new stake in Black Diamond Therapeutics in the 4th quarter valued at about $49,000. Institutional investors and hedge funds own 95.47% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on BDTX shares. Wedbush reissued an "outperform" rating and issued a $11.00 price target on shares of Black Diamond Therapeutics in a research note on Wednesday, March 19th. HC Wainwright increased their price target on shares of Black Diamond Therapeutics from $11.00 to $12.00 and gave the company a "buy" rating in a research note on Tuesday, March 18th. Finally, Stifel Nicolaus dropped their price target on shares of Black Diamond Therapeutics from $16.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, March 7th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Black Diamond Therapeutics presently has an average rating of "Buy" and an average target price of $14.60.

Black Diamond Therapeutics Stock Performance

Shares of NASDAQ:BDTX remained flat at $1.60 during mid-day trading on Tuesday. 361,848 shares of the company were exchanged, compared to its average volume of 1,474,225. Black Diamond Therapeutics, Inc. has a 1 year low of $1.20 and a 1 year high of $7.66. The company has a market cap of $90.68 million, a price-to-earnings ratio of -1.20 and a beta of 2.81. The company has a 50-day moving average price of $1.66 and a 200-day moving average price of $2.25.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.03. On average, research analysts predict that Black Diamond Therapeutics, Inc. will post -1.3 earnings per share for the current year.

Insiders Place Their Bets

In other news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of the stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $2.07, for a total value of $11,973,484.44. Following the transaction, the insider now owns 2,733,547 shares in the company, valued at approximately $5,658,442.29. This represents a 67.91 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 8.87% of the stock is owned by company insiders.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.